DIGOXIN KERN PHARMA 0.25 MG

Země: Izrael

Jazyk: angličtina

Zdroj: Ministry of Health

Aktivní složka:

DIGOXIN

Dostupné s:

TRIMA ISRAEL PHARMACEUTICAL PRODUCTS MAABAROT LTD

ATC kód:

C01AA05

Léková forma:

TABLETS

Složení:

DIGOXIN 0.25 MG

Podání:

PER OS

Druh předpisu:

Required

Výrobce:

KERN PHARMA S.L, SPAIN

Terapeutické oblasti:

DIGOXIN

Terapeutické indikace:

Cardiac failure:Digoxin KERN PHARMA is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. The greatest therapeutic benefit is achieved in patients with ventricular dilatation.Digoxin KERN PHARMA is specifically indicated where cardiac failure is accompanied by atrial fibrilation.Supraventricular arrhythmias:Digoxin KERN PHARMA is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.

Datum autorizace:

2018-12-31

Informace pro uživatele

.اضيأ نينجلا
عاضرلإا
تاعضرملا ءاسنلل نكمي ،كلذل .ادج ةريغص
تايمكب نكل ،ملأا بيلح للاخ نم ءاودلا
اذه زارفإ متي
.ءاودلا اذه لامعتسا
ةبوصخلا
.ةبوصخلا ىلع نيسكوچيد ريثأتل ةبسنلاب
تامولعم دجوت لا
تانيكاملا لامعتساو ةقايسلا
نم رذحلا كيلع بجيف ،رفصلأا نوللاب
ةيؤرلا وأ ةشوشم ةيؤرو راود نع غلابلإا
مت هنلأ
ً
ارظن
.ةريطخ تاطاشن يف ةكراشملا وأ تانيكاملا
لامعتسا ،ةبكرملا ةقايس
ءاودلا تاب
ّ
كرم نم مسق نع ة
ّ
مهم تامولعم
ةنيعم عاونلأ لامتحا مدع كيدل نإ بيبطلا
كل لاق اذإ )ركسلا نم عون( زوتكلالا ىلع
ءاودلا يوتحي
.ءاودلا اذه لوانت لبق بيبطلا رشتساف
،ركسلا نم .3
؟ءاودلا لمعتست فيك
وأ بيبطلا عم صحفلا كيلع بجي .بيبطلا
تاميلعت ب
َ
سح ا
ً
مئاد رضحتسملا لامعتسا بجي
ةقيرطو ةعرجلا .رضحتسملاب جلاعلا
ةقيرطبو ةعرجلاب قلعتي اميف ا
ً
د
ّ
كأتم نكت مل اذإ
ّ
يلديصلا
)ىلكلا ءادأو نزولا ،نسلا( ةيصخش تايطعم
ىلع ادامتعا ،طقف ،بيبطلا امهد
ّ
دحيس جلاعلا
.اهنم يناعت يتلا بلقلا لكاشمو
ىضرملا وأ نسلا رابك ىضرملا ىدل )ةمادإو
ليمحت( ةعرجلا رييغتل تايصوتب بيبطلا
ركفيس
.ضفخنم يولك طاشن نم نوناعي نيذلا
:جلاعلل ناتلحرم كانه نوكت ام ةداع
كلذ لجأ نم .ةعرسب مدلا يف ءاودلا ىوتسم
عفر وه ةعرجلا هذه نم فدهلا – "ليمحتلا
ةعرج"
ةعرج لوانت وأ ةموادملا ةعرج ىلإ
لاقتنلاا اروف كلذ

Charakteristika produktu

‏
SUMMARY OF PRODUCT CHARACTERISTICS
NAME OF THE MEDICINAL PRODUCT
Digoxin KERN PHARMA 0.25 mg tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Digoxin KERN PHARMA 0.25 mg tablets
Each tablet contains:
Digoxin. . . . . . . . . . 0.25 mg
Lactose monohydrate 95.52 mg, maize starch, hydrolysed maize starch,
rice starch and other
excipients.
For a full list of excipients, see section 6.1
PHARMACEUTICAL FORM
Digoxin KERN PHARMA 0.25 mg tablets:
Round, biconvex, white tablets scored on both sides. The purpose of
the score line is to
facilitate breaking of the tablet for ease of swallowing or, if
necessary, for dividing
into equal doses .
CLINICAL PARTICULARS:
THERAPEUTIC INDICATIONS
Cardiac failure:
Digoxin KERN PHARMA is indicated for the treatment of chronic cardiac
failure where the principal
cause is systolic dysfunction. The greatest therapeutic benefit is
achieved in patients with ventricular
dilatation.
Digoxin KERN PHARMA is specifically indicated where cardiac failure is
accompanied by atrial
fibrillation.
Supraventricular arrhythmias:
Digoxin KERN PHARMA is indicated for the treatment of certain
supraventricular arrhythmias,
particularly
atrial
fibrillation
and
flutter,
where
its
principal
beneficial
effect
is
to reduce
the
ventricular rate.
POSOLOGY AND METHOD OF ADMINISTRATION
The dose of Digoxin KERN PHARMA for each patient must be tailored
individually according to
age, lean body weight, and renal function. The suggested doses are
intended only as an initial guide.
ADULTS AND CHILDREN OVER 10 YEARS:
_Rapid oral administration:_
0.75 to 1.5 mg as a single dose.
‏
In less urgent cases, or when there is a major risk of toxicity, for
example in the elderly, the oral
loading dose should be administered in divided doses at intervals of 6
hours, with approximately half
of the total dose given as the first dose. The clinical response
should be assessed before giving each
additional dose (see Special warnings and precautions for use).
_Slow oral administration:_
0.25 to 0.75 mg should be administered daily for